跳至主要内容
临床试验/NCT01852708
NCT01852708已完成不适用

Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood

Natera, Inc.9 个研究点 分布在 3 个国家目标入组 1,059 人开始时间: 2012年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Natera, Inc.
入组人数
1,059
试验地点
9
主要终点
Sensitivity and Specificity of testing

研究概览

简要总结

The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

详细描述

The goal of this study is to further develop a non-invasive prenatal blood test that can diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in the mother's bloodstream during pregnancy.

Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or extra pieces of DNA that can cause problems), aneuploidy (trisomy 21, 18, or 13) or other genetic disorders will be asked to participate.

If this study is successful, it will reduce the need for invasive procedures during pregnancy such as amniocentesis and chorionic villus sampling (CVS) but still enable women to find out accurate information regarding their baby's health early in the pregnancy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 or older at enrollment
  • Gestation age of at least 9 weeks, 0 days by best obstetrical estimate
  • One or more fetuses with a clinically confirmed diagnosis of a genetic variant of interest via karyotype, FISH, chromosomal microarray or other genetic assay AND/OR
  • One or more fetuses with any variant of fetal structure that is expected to require medical or surgical intervention in the newborn period, shorten lifespan, affect intellectual development or otherwise indicate a genetic anomaly AND/OR
  • Positive high risk noninvasive prenatal screening or serum screening result
  • Able to provide informed consent

排除标准

  • Maternal history of bone marrow or organ transplantation

结局指标

主要结局

Sensitivity and Specificity of testing

时间窗: 1 year

Sensitivity and Specificity of the test to diagnose microdeletions (eg. 22q and 5p-) and aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.

次要结局

未报告次要终点

研究者

发起方
Natera, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验